BIOMARIN PHARMACEUTICAL INC Tax Withholding Paid on Stock Awards
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Tax Withholding Paid on Stock Awards of $39.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $11.32M, a 8.01% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $28.18M, a 27.33% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $2.70M, a 45.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $2.18M, a 63.19% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC payment, tax withholding, share-based payment arrangement for fiscal 2025 was $55.97M, a 27.84% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC payment, tax withholding, share-based payment arrangement for fiscal 2024 was $77.56M, a 1.63% increase from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC payment, tax withholding, share-based payment arrangement for fiscal 2023 was $76.32M, a 40.59% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC payment, tax withholding, share-based payment arrangement for fiscal 2022 was $54.28M, a 18.51% increase from fiscal 2021.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $39.50M 10-Q · filed 2026-08-06 | $42.20M derived: sum of 3 quarters · filed 2026-08-06 | $44.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $28.18M 10-Q · filed 2026-05-05 | $30.88M derived: sum of 2 quarters · filed 2026-05-05 | $33.06M derived: sum of 3 quarters · filed 2026-05-05 | $45.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.88M derived: sum of 2 quarters · filed 2026-02-26 | $17.19M derived: sum of 3 quarters · filed 2026-08-06 | $55.97M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $14.49M derived: sum of 2 quarters · filed 2026-08-06 | $53.27M 10-Q · filed 2025-10-28 | $58.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $12.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $51.09M 10-Q · filed 2026-08-06 | $56.00M derived: sum of 3 quarters · filed 2026-08-06 | $61.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $38.78M 10-Q · filed 2026-05-05 | $43.69M derived: sum of 2 quarters · filed 2026-05-05 | $49.60M derived: sum of 3 quarters · filed 2026-05-05 | $66.39M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.82M derived: sum of 2 quarters · filed 2026-02-26 | $27.61M derived: sum of 3 quarters · filed 2026-02-26 | $77.56M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $22.70M derived: sum of 2 quarters · filed 2025-10-28 | $72.65M 10-Q · filed 2025-10-28 | $76.57M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $16.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $66.74M 10-Q · filed 2025-08-05 | $70.66M derived: sum of 3 quarters · filed 2026-02-26 | $75.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $49.95M 10-Q · filed 2025-05-02 | $53.87M derived: sum of 2 quarters · filed 2026-02-26 | $58.41M derived: sum of 3 quarters · filed 2026-02-26 | $74.84M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.46M derived: sum of 2 quarters · filed 2026-02-26 | $24.90M derived: sum of 3 quarters · filed 2026-02-26 | $76.32M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $20.98M derived: sum of 2 quarters · filed 2024-10-31 | $72.40M 10-Q · filed 2024-10-31 | $75.99M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | $16.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $67.86M 10-Q · filed 2024-08-05 | $71.45M derived: sum of 3 quarters · filed 2025-02-24 | $77.77M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | $51.42M 10-Q · filed 2024-04-26 | $55.01M derived: sum of 2 quarters · filed 2025-02-24 | $61.33M derived: sum of 3 quarters · filed 2025-02-24 | $72.76M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $9.91M derived: sum of 2 quarters · filed 2025-02-24 | $21.33M derived: sum of 3 quarters · filed 2025-02-24 | $54.28M 10-K · filed 2025-02-24 |
| 2022-09-30 | $6.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $17.75M derived: sum of 2 quarters · filed 2023-11-02 | $50.70M 10-Q · filed 2023-11-02 | $52.07M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $11.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $44.38M 10-Q · filed 2023-08-02 | $45.75M derived: sum of 3 quarters · filed 2024-02-26 | $51.45M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $32.95M 10-Q · filed 2023-04-28 | $34.33M derived: sum of 2 quarters · filed 2024-02-26 | $40.02M derived: sum of 3 quarters · filed 2024-02-26 | $49.66M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $7.07M derived: sum of 2 quarters · filed 2024-02-26 | $16.71M derived: sum of 3 quarters · filed 2024-02-26 | $45.80M 10-K · filed 2024-02-26 |
| 2021-09-30 | $5.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $15.33M derived: sum of 2 quarters · filed 2022-10-28 | $44.43M 10-Q · filed 2022-10-28 | $46.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $9.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $38.73M 10-Q · filed 2022-08-04 | $40.70M derived: sum of 3 quarters · filed 2023-02-27 | $46.72M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $29.10M 10-Q · filed 2022-04-29 | $31.07M derived: sum of 2 quarters · filed 2023-02-27 | $37.09M derived: sum of 3 quarters · filed 2023-02-27 | $44.89M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $7.99M derived: sum of 2 quarters · filed 2023-02-27 | $15.79M derived: sum of 3 quarters · filed 2023-02-27 | $44.64M 10-K · filed 2023-02-27 |
| 2020-09-30 | $6.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $13.82M derived: sum of 2 quarters · filed 2021-10-29 | $42.67M 10-Q · filed 2021-10-29 | $44.40M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $7.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $36.65M 10-Q · filed 2021-07-30 | $38.37M derived: sum of 3 quarters · filed 2022-02-25 | $42.42M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $28.84M 10-Q · filed 2021-04-30 | $30.57M derived: sum of 2 quarters · filed 2022-02-25 | $34.62M derived: sum of 3 quarters · filed 2022-02-25 | $41.42M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $5.78M derived: sum of 2 quarters · filed 2022-02-25 | $12.57M derived: sum of 3 quarters · filed 2022-02-25 | $42.68M 10-K · filed 2022-02-25 |
| 2019-09-30 | $4.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $10.85M derived: sum of 2 quarters · filed 2020-11-06 | $40.95M 10-Q · filed 2020-11-06 | $42.69M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $6.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $36.90M 10-Q · filed 2020-08-05 | $38.64M derived: sum of 3 quarters · filed 2021-02-26 | $44.20M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $30.11M 10-Q · filed 2020-05-01 | $31.84M derived: sum of 2 quarters · filed 2021-02-26 | $37.41M derived: sum of 3 quarters · filed 2021-02-26 | $43.13M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.74M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | $7.30M derived: sum of 2 quarters · filed 2021-02-26 | $13.02M derived: sum of 3 quarters · filed 2021-02-26 | $35.92M 10-K · filed 2021-02-26 |
| 2018-09-30 | $5.57M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | $11.28M derived: sum of 2 quarters · filed 2019-11-04 | $34.18M 10-Q/A · filed 2019-11-04 | $35.82M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $5.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $28.61M 10-Q · filed 2019-08-02 | $30.26M derived: sum of 3 quarters · filed 2020-02-27 | $35.50M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $22.90M 10-Q · filed 2019-04-29 | $24.54M derived: sum of 2 quarters · filed 2020-02-27 | $29.78M derived: sum of 3 quarters · filed 2020-02-27 | $38.47M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $6.88M derived: sum of 2 quarters · filed 2020-02-27 | $15.57M derived: sum of 3 quarters · filed 2020-02-27 | $33.51M 10-K · filed 2020-02-27 |
| 2017-09-30 | $5.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $13.93M derived: sum of 2 quarters · filed 2018-10-26 | $31.86M 10-Q · filed 2018-10-26 | $36.09M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $8.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $26.62M 10-Q · filed 2018-08-03 | $30.85M derived: sum of 3 quarters · filed 2019-02-28 | $33.27M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $17.93M 10-Q · filed 2018-04-27 | $22.16M derived: sum of 2 quarters · filed 2019-02-28 | $24.58M derived: sum of 3 quarters · filed 2019-02-28 | $36.62M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $6.64M derived: sum of 2 quarters · filed 2019-02-28 | $18.68M derived: sum of 3 quarters · filed 2019-02-28 | $59.47M 10-K · filed 2019-02-28 |
| 2016-09-30 | $2.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $14.45M derived: sum of 2 quarters · filed 2017-10-31 | $55.24M 10-Q · filed 2017-10-31 | $56.26M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $12.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $52.82M 10-Q · filed 2017-08-02 | $53.84M derived: sum of 3 quarters · filed 2018-02-26 | $56.25M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $40.79M 10-Q · filed 2017-05-04 | $41.81M derived: sum of 2 quarters · filed 2018-02-26 | $44.21M derived: sum of 3 quarters · filed 2018-02-26 | $63.04M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $3.42M derived: sum of 2 quarters · filed 2018-02-26 | $22.25M derived: sum of 3 quarters · filed 2018-02-26 | $22.99M 10-K · filed 2018-02-26 |
| 2015-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $21.23M derived: sum of 2 quarters · filed 2016-11-03 | $21.97M 10-Q · filed 2016-11-03 | $22.49M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $18.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $19.57M 10-Q · filed 2016-08-08 | $20.09M derived: sum of 3 quarters · filed 2017-02-27 | $20.64M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $735.00K 10-Q · filed 2016-05-02 | $1.26M derived: sum of 2 quarters · filed 2017-02-27 | $1.81M derived: sum of 3 quarters · filed 2017-02-27 | $8.03M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $522.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $1.07M derived: sum of 2 quarters · filed 2017-02-27 | $7.29M derived: sum of 3 quarters · filed 2017-02-27 | $7.77M 10-K · filed 2017-02-27 |
| 2014-09-30 | $552.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $6.77M derived: sum of 2 quarters · filed 2015-11-02 | $7.25M 10-Q · filed 2015-11-02 | $7.50M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $6.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $6.69M 10-Q · filed 2015-08-05 | $6.95M derived: sum of 3 quarters · filed 2016-02-29 | $7.10M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $473.00K 10-Q · filed 2015-05-05 | $729.00K derived: sum of 2 quarters · filed 2016-02-29 | $883.00K derived: sum of 3 quarters · filed 2016-02-29 | $6.64M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $256.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $410.00K derived: sum of 2 quarters · filed 2016-02-29 | $6.17M derived: sum of 3 quarters · filed 2016-02-29 | $6.40M 10-K · filed 2016-02-29 |
| 2013-09-30 | $154.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $5.92M derived: sum of 2 quarters · filed 2014-10-28 | $6.14M 10-Q · filed 2014-10-28 | |
| 2013-06-30 | $5.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $5.99M 10-Q · filed 2014-07-31 | ||
| 2013-03-31 | $225.00K 10-Q · filed 2014-05-02 | |||
| 2012-12-31 | $1.66M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |